White Oak Regulatory Tox at ACT 2026

Nov 15–18, 2026 San Antonio, TX ~1.4k attendees Website

White Oak Regulatory Tox takes part in 3 sessions at ACT 2026 in San Antonio. Its program centres on carcinogenicity assessment that weighs all the evidence, with new approach methods in a supporting role. It also covers the foundations of choosing a first-in-human dose.

Organization	ACT 2026 Attendance
White Oak Regulatory Tox	◇Bronze Supporter
whiteoakregtox.com ConsultanciesBronze Supporter Consultancy run by former FDA reviewers on nonclinical strategy, regulatory toxicology, pre-review of filings and asset due diligence.	Talk Sun Nov 15 8:00am–8:20am Part of First-in-Human Dose Selection: Translational Strategies and Special Considerations across Modalities and Organ Systems (CE1) Foundational Approaches to FIH Dose Selection (CE1-1) Translational safety Session Wed Nov 18 9:00am–12:00pm The Future of Nonclinical Carcinogenicity Testing: NAMs in a Weight-of-Evidence Paradigm Shift (S15) Genetic toxicology · New approach methods · with HESI 9:00amFrom Rodent Bioassays to Mechanistic Evidence: The Future of Carcinogenicity Assessment (S15-1)HESI 9:15amCarcinogenicity Assessments Based on a Weight of Evidence Approach and the Role of NAMs in Supporting This Approach (S15-2)White Oak Regulatory Tox 9:45amIntegrating Error-Corrected Sequencing into OECD Test Guidelines: Advancing Precision Mutagenesis in Regulatory Toxicology (S15-3)Health Canada 10:45amAssessing Clonal Expansion of Cancer Driver Mutants as an Early Cancer Biomarker (S15-4)U.S. Food and Drug Administration 11:15amIndustry Perspectives on Advanced Methods for Carcinogenicity Risk Assessment (S15-5)GSK Talk Wed Nov 18 9:15am–9:45am Part of The Future of Nonclinical Carcinogenicity Testing: NAMs in a Weight-of-Evidence Paradigm Shift (S15) Carcinogenicity Assessments Based on a Weight of Evidence Approach and the Role of NAMs in Supporting This Approach (S15-2) Genetic toxicology · New approach methods

Organization

ACT 2026 Attendance

White Oak Regulatory Tox

◇Bronze Supporter

whiteoakregtox.com

ConsultanciesBronze Supporter

Consultancy run by former FDA reviewers on nonclinical strategy, regulatory toxicology, pre-review of filings and asset due diligence.

Talk

Sun Nov 15
8:00am–8:20am

Part of First-in-Human Dose Selection: Translational Strategies and Special Considerations across Modalities and Organ Systems (CE1)

Foundational Approaches to FIH Dose Selection (CE1-1)

Translational safety

Session

Wed Nov 18
9:00am–12:00pm

The Future of Nonclinical Carcinogenicity Testing: NAMs in a Weight-of-Evidence Paradigm Shift (S15)

Genetic toxicology · New approach methods · with HESI

9:00amFrom Rodent Bioassays to Mechanistic Evidence: The Future of Carcinogenicity Assessment (S15-1)HESI
9:15amCarcinogenicity Assessments Based on a Weight of Evidence Approach and the Role of NAMs in Supporting This Approach (S15-2)White Oak Regulatory Tox
9:45amIntegrating Error-Corrected Sequencing into OECD Test Guidelines: Advancing Precision Mutagenesis in Regulatory Toxicology (S15-3)Health Canada
10:45amAssessing Clonal Expansion of Cancer Driver Mutants as an Early Cancer Biomarker (S15-4)U.S. Food and Drug Administration
11:15amIndustry Perspectives on Advanced Methods for Carcinogenicity Risk Assessment (S15-5)GSK

Talk

Wed Nov 18
9:15am–9:45am

Part of The Future of Nonclinical Carcinogenicity Testing: NAMs in a Weight-of-Evidence Paradigm Shift (S15)

Carcinogenicity Assessments Based on a Weight of Evidence Approach and the Role of NAMs in Supporting This Approach (S15-2)

Genetic toxicology · New approach methods

Instantly find 20 buyers from White Oak Regulatory Tox

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the American College of Toxicology (ACT). Organization details are derived from ACT’s published program, exhibitor floor plan and supporter list, and each organization’s own website. Submit a correction